Ralph Weichselbaum, MD, the Daniel K. Ludwig Distinguished Service Professor of Radiation and Cellular Oncology at the University of Chicago, is the guest of honor on today’s show focusing on radiation oncology as a discipline: the changes that have occurred over the years, the state of the field today, and how the field projects over the next few years. Dr. Weichselbaum highlights the malignancies that are poised for improvements in radiation outcomes in the coming years, how little attention is paid to radiation oncology in medical school, the potential of proton therapy and the need for prospective randomized controlled trials in some diseases, and a Lancet Oncology paper he reacted strongly to on Twitter.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
